Effect of azilsartan on 24-h ambulatory blood pressure in patients with CKD and hypertension.

Effect of azilsartan on 24-h ambulatory blood pressure in patients with CKD and hypertension. - Effect of azilsartan on 24-h ambulatory blood pressure in CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012931

Enrollment

Registered

2015-02-01

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD and hypertension

Interventions

This was a open, cross-over (azilsartan or other ARB) study of 12 weeks&#39

duration in 20 patients with CKD and hypertension.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria were following; -outpatient -a steady dose of ARB other than azilsartan -without hyperkalemia and progression of renal damage by ARB -instructed nutritional guidance -take ARBs for over 3 months -BP of >130/80 mmHg of the run-in period -ABPM was done within 6 months

Exclusion criteria

Exclusion criteria: Exclusion criteria were known hypersensitivity to ARBs, ACE inhibitors or direct renin inhibitors and pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
The primary endpoint was 24-h systolic BP by ambulatory monitoring.	—

Countries

Japan

Contacts

Public ContactKatsuomi Matsui

St. Marianna University School of Medicine Department of Nephrology and Hypertension, Internal Medicine

m.katsuomi@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026